Searchable abstracts of presentations at key conferences in endocrinology

ea0025p38 | Clinical biochemistry | SFEBES2011

Hypocalcaemia presenting via an acute medical admissions unit is only rarely adequately investigated

Griffiths Rebecca , Pattman Stewart , Quinton Richard

Aim: To determine whether cases of hypocalcaemia presenting via an emergency medical admissions unit (EAU) are appropriately investigated.Background: Hypocalcaemia is a potentially life threatening abnormality, with a prevalence of 18% among hospital inpatients.1,2 Risk factors include vitamin D deficiency, renal disease, hypoparathyroidism (typically post-neck surgery) and hypomagnesaemia. A reasonable investigational dataset comprises U+Es a...

ea0008p67 | Neuroendocrinology and behaviour | SFE2004

PITUITARY FUNCTION IN ADULTS TREATED FOR ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) DURING CHILDHOOD

McGregor EJ , Jenkinson H , Griffiths A , Toogood AA

Acute lymphoblastic leukaemia is the commonest malignancy to occur during childhood. Treatment protocols included prophylactic cranial radiotherapy at doses of 18-24Gy. Radiation to the hypothalamic-pituitary axis causes hypopituitarism, the severity of which depends upon the dose and time from treatment. Adults who received 24Gy up to 25 years ago have been shown to be GH deficient, those who received 18Gy were not. Other pituitary function was reported be normal. The purpose...

ea0028p66 | Clinical practice/governance and case reports | SFEBES2012

Correcting hyponatraemia on the AMU: learn to walk before you can run?

Webb David , Witherall Ruth , Ellis Holly , Griffiths Adam , Levy Miles

Introduction: Significant hyponatraemia (serum sodium <128 mmol/l) is a potentially modifiable cause of prolonged hospital length of stay (LOS). By correcting euvolaemic hyponatraemia more rapidly than imposed fluid restriction, vasopressin receptor-2 antagonists may be useful adjuncts to existing treatments.Aim: To explore the potential clinical utility of vasopressin antagonists by describing the frequency and nature of hyponatraemia typically enco...

ea0020p262 | Bone/Calcium | ECE2009

Thyrotoxicosis presenting as severe life-threatening hypocalcaemia – a case report

Loh Vooi-Lee , Boston-Griffiths Edney , Rodin Andrew , Hyer Steve

Introduction: Hypocalcaemia is a rare presentation of thyrotoxicosis. We describe a patient with severe life-threatening hypocalcaemia and suggest pathogenic mechanisms.Case report: A 66-year old lady with long-standing insulin-treated type 2 diabetes presented acutely with generalised weakness and a collapse at home. Prior to admission, she had been treated for an infected neuro-ischaemic plantar ulcer with broad-spectrum antibiotics. She had developed ...

ea0015p103 | Clinical practice/governance and case reports | SFEBES2008

11 Beta-hydroxysteroid dehydrogenase 2 activity in septic shock before and during treatment with hydrocortisone

Lloyd LA , Wayte A , Griffiths K , Thorpe CM , Taylor NF , Wilton A

Hydrocortisone treatment in septic shock promotes shock reversal and reduces mortality. We hypothesised the doses that used (200–300 mg/2 h) would result in plasma cortisol levels sufficient to saturate the 11 beta-hydroxysteroid dehydrogenase 2 enzyme (11 beta-HSD 2) with cortisol inactivation overload. Consequently cortisol would access the mineralocorticoid receptor producing mineralocorticoid effects. Hypertensive metabolic alkalotic effects would tend to counteract t...

ea0012p106 | Reproduction | SFE2006

Preliminary investigation on the effects of prostaglandin EP2 and EP4 agonists on isolated uterus from non-pregnant and pregnant mice

Griffiths AL , Marshall KM , Senior J , Woodward DF

The aim of this study was to compare the effects of prostaglandin EP2 – and EP4 -receptor agonists on uterine tissue taken from non-pregnant and pregnant mice.Uterine tissue was taken from non-pregnant animals during dioestrus and from pregnant animals on day 18 of gestation. Samples were set-up for superfusion (Krebs’ solution with 1 μM indometacin at 2 ml/min and 37 °C) as previously described by Senior et a...

ea0011p701 | Reproduction | ECE2006

Metformin therapy decreases hyperandrogenism and hyperinsulinaemia in women with polycystic ovary syndrome

Abdalla TME , Wilton D , Wilton A , Wayte A , Griffiths K , Huber J

Insulin resistance has been suggested to have a pathogenic role in polycystic ovary syndrome (PCOS). The use of insulin sensitising drugs might therefore have a therapeutic role in its management.We studied 20 patients (mean age 32.6 years) with PCOS (diagnosed by the Rotterdam Consensus Workshop group criteria, 2003) before and after treatment with metformin (1.5–3 grams daily) for 6 to 12 months.Clinical features studied wer...

ea0011p702 | Reproduction | ECE2006

A unique subgroup of patients with polycystic ovary syndrome identified by clinical and biochemical features

Abdalla TME , Wilton A , Wilton D , Griffiths K , Wayte A , Huber J

Hyperandrogenism of adrenal origin evidenced by elevated dehydroepiandrosterone sulphate (DHEAS) levels has been reported in 20% to 30% of patients with polycystic ovary syndrome.We studied 50 patients with PCOS (defined by the Rotterdam Consensus Workshop group criteria, 2003). Adrenal hyperandrogenaemia was defined as a DHEAS level> 10.5 micromoles/litre was found in 10 patients (20%). Clinical features studied were body mass index (BMI) and hirsut...

ea0010p71 | Reproduction | SFE2005

The effect of prostaglandin E2, sulprostone and isoprenaline on isolated mouse uterine tissue taken during labour

Griffiths A , Marshall K , Senior J , OaDonovan P , Farrar D

The aim of this study was to compare the effects of prostaglandin E2 (PGE2) and a PGE analogue, sulprostone with isoprenaline (β1/β2 agonist) on mouse uterine tissue taken during labour.Uterine tissue was taken and set up for superfusion (Krebs’ solution at 2 ml/min and 37°C) as previously described by Senior et al (1991). After allowing the tissue to equilibrate for approximately 20 ...

ea0051oc5.7 | Oral Communications 5 | BSPED2017

The Phenotyping of Overgrowth (POD) Study: a novel ‘no win, no fee’ model for translating research findings into clinical diagnoses

Foster Alison , Antoniadi Thalia , Wallis Yvonne , Griffiths Mike , Lim Derek , Cole Trevor , Barrett Tim

Introduction: Rare genetic overgrowth disorders are a group of conditions characterised by height and/or head circumference >2 S.D. above the mean for age and sex, learning disability, congenital anomalies, and in some cases childhood tumours. POD is a national cohort study that includes a next generation sequencing (NGS) panel of overgrowth genes. We present a new model for clinical confirmation of pathogenic variants identified by this research panel. Clin...